Drugs / vididencel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07651878 | Apr 2026 → Sep 2029 expected | chronic myeloid leukemia | Mendus | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 25
| Date | Issuer | Release |
|---|---|---|
| 2026-09-11 | Mendus | Results Mendus reports positive read-out for first stage VITAL-CML trial mendus.com ↗
The company now reports that a review by the DSMB concluded that the combination of vididencel and TKI treatment did not raise any safety or tolerability concerns, based on 8 patients who completed 4 doses of vididencel. |
| 2026-06-02 | Mendus | Results Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer mendus.com ↗
The data show that vididencel induces broad anti-tumor immune responses associated with improved progression-free survival, supporting its potential as a combination immunotherapy for this difficult-to-treat cancer. |
| 2026-05-13 | Mendus | Results Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments mendus.com ↗
The research presented at CIMT confirms that vididencel can be combined with a broad range of TKIs used for the treatment of CML and that the immune-activating properties of vididencel are unaffected by asciminib. |
| 2025-12-10 | Mendus | Results Mendus Announces Summary of Data Presented at ASH mendus.com ↗
Updated results from the European ADVANCE II Phase 2 trial continue to demonstrate robust relapse-free and overall survival benefit in a high-risk AML population, based on the presence of persistent measurable residual disease (MRD) following IC. |
| 2025-11-27 | Mendus | Results ALISON trial long-term follow-up confirms safety, tolerability and feasibility of vididencel as an active immunotherapy in high-risk ovarian cancer mendus.com ↗
The data confirms safety, tolerability and feasibility of Mendus’ lead product vididencel as an active immunotherapy in high-risk ovarian cancer and provides the basis for novel combination treatments in this indication. |
| 2025-07-23 | Mendus | Regulatory Mendus granted US patent for use of vididencel in ovarian cancer mendus.com ↗
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent in the US covering the use of Mendus’ lead product vididencel in ovarian cancer. |
| 2025-06-16 | Mendus | Results Data presented at EHA strengthens Mendus’ programs in myeloid leukemias mendus.com ↗
The clinical data presented based on the European ADVANCE II Phase 2 clinical trial confirms that vididencel acts as a mutation-agnostic immunotherapy in acute myeloid leukemia (AML), supporting a broad positioning as post-clinical remission therapy, independent of specific mutations in this indication. |
| 2025-06-02 | Mendus | Results ALISON trial data presented at ASCO 2025 demonstrates successful induction of tumor-directed immune responses in high-risk ovarian cancer mendus.com ↗
The data demonstrate that stable disease is associated with the successful induction of tumor-directed immune responses following vididencel treatment in this indication. |
| 2025-05-14 | Mendus | Results Mendus presents AML and solid tumor program data at CIMT mendus.com ↗
The data demonstrate increased T cell diversity following treatment with Mendus’ lead product vididencel in acute myeloid leukemia (AML) and support the use of Mendus’ DCOne platform to expand tumor-infiltrating lymphocytes for the treatment of solid tumors. |
| 2025-01-02 | Mendus | Regulatory FDA and EMA feedback endorses vididencel registration trial preparations mendus.com ↗
Both FDA and EMA supported the trial design, patient population, reference therapy, primary and secondary endpoints and statistical analysis strategy, as proposed by Mendus. |
| 2024-12-18 | Mendus | Results Mendus and UMCG announce positive topline data from the ALISON trial with vididencel in ovarian cancer mendus.com ↗
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces positive topline data from the ALISON Phase 1 clinical trial with its lead product vididencel in ovarian cancer. |
| 2024-12-09 | Mendus | Results Updated data from the ADVANCE II Phase 2 trial presented at ASH demonstrate durable survival of AML patients treated with vididencel mendus.com ↗
The data showed that the majority of AML patients treated with vididencel remain alive and disease-free in long-term follow-up, with a median follow-up of 41.8 months. |
| 2024-06-20 | Mendus | Results ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel mendus.com ↗
Vididencel-induced immune responses against tumor antigens that are regularly upregulated in HGSC were observed in 10 out of 15 patients evaluated so far, with 3 patients not reaching a vaccine induced response (VIR) due to high baseline responses. |
| 2024-06-17 | Mendus | Results Mendus data presented at EHA substantiate the potential of vididencel to induce functional, clinically relevant immune responses in AML mendus.com ↗
All patients with confirmed T cell responses against tumor antigens following vididencel treatment were alive in long-term follow-up at the time of read-out. |
| 2024-05-16 | Mendus | Results Mendus announces presentation of multiple abstracts during the 2024 CIMT Annual Meeting mendus.com ↗
The data demonstrate the potential of vididencel to induce broad immune responses in AML patients, which are associated with improved survival. |
| 2023-12-11 | Mendus | Results Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 mendus.com ↗
The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from the current standard of care in AML maintenance therapy. |
| 2023-11-06 | Mendus | Results Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023 mendus.com ↗
The data demonstrate the boosting of broad immune responses in the majority of patients and a continued strong safety profile of vididencel. |
| 2023-11-03 | Mendus | Results Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal mendus.com ↗
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of additional Phase 1 clinical trial data on its lead development program vididencel in the peer-reviewed medical journal HemaSphere. |
| 2023-09-21 | Mendus | Results Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23 mendus.com ↗
The data further validate vididencel’s proposed mechanism of action and demonstrate that immune responses triggered by the cell-based cancer vaccine in patients with Acute Myeloid Leukemia (AML) and ovarian cancer are largely comparable. |
| 2023-09-08 | Mendus | Regulatory Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML) mendus.com ↗
The Fast Track Designation granted by the FDA adds substantial regulatory value to the vididencel program in the most important healthcare market worldwide. |
| 2023-06-19 | Mendus | Regulatory Mendus receives ATMP certificate from European Medicines Agency supporting its lead pipeline program vididencel mendus.com ↗ |
| 2023-06-12 | Mendus | Results Mendus presents comprehensive ADVANCE II immunomonitoring data at the EHA Annual Meeting 2023 mendus.com ↗
The data demonstrate that vididencel treatment led to increased levels of activated, cancer-killing T cells and reduced levels of inhibitory, immune-suppressive T cells in the majority of patients. |
| 2023-04-26 | Mendus | Results Mendus announces two upcoming presentations at the 2023 CIMT Annual Meeting mendus.com ↗
Abstract #58, to be featured in an oral presentation, summarizes novel immunomonitoring data from the ADVANCE II trial, a Phase 2 monotherapy trial studying Mendus’ lead program vididencel (DCP-001) as a novel maintenance treatment modality in AML. |
| 2023-04-19 | Mendus | Results Mendus announces positive data from the ALISON trial in ovarian cancer presented at the AACR Annual Meeting 2023 mendus.com ↗
The data presented at AACR demonstrate that vididencel treatment is safe, well-tolerated and induces durable T-cell responses to tumor associated antigens in ovarian cancer patients. |
| 2023-03-15 | Mendus | Results Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023 mendus.com ↗
The ALISON study is progressing well, and the initial read-out with respect to improvements in the patients’ immune cell status and T-cell responses induced by our vaccine are encouraging. |
All press releases naming this drug 34 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vididencel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07651878 ↗ |
| Modality | Cell therapy | “cell therapy vididencel” NCT07651878 ↗ |